Mus musculus
Ontology highlight
ABSTRACT:
OTHER RELATED OMICS DATASETS IN: E-GEOD-40377
PROVIDER: PRJNA173797 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:Microarray profiling of WT or PDE10A KO mice treated with vehicle or a PDE10 inhibitor
2015-10-01 | E-GEOD-40377 | ExpressionAtlas
Project description:Inhibition of phosphodiesterase 10A (PDE10A) promotes cyclic nucleotide signaling, increases striatal activation, and decreases behavioral activity. Enhanced cyclic nucleotide signaling is a well established route to producing changes in gene expression. We hypothesized that chronic suppression of PDE10A activity would have significant effects on gene expression in the striatum. A comparison of the expression profile of PDE10A knockout (KO) mice and wild-type mice after chronic PDE10A inhibition revealed altered expression of 19 overlapping genes with few significant changes outside the striatum or after administration of a PDE10A inhibitor to KO animals. Chronic inhibition of PDE10A produced up-regulation of mRNAs encoding genes that included prodynorphin, synaptotagmin10, phosphodiesterase 1C, glutamate decarboxylase 1, and diacylglycerol O-acyltransferase and a down-regulation of mRNAs encoding choline acetyltransferase and Kv1.6, suggesting long-term suppression of the PDE10A enzyme is consistent with altered striatal excitability and potential utility as a antipsychotic therapy. In addition, up-regulation of mRNAs encoding histone 3 (H3) and down-regulation of histone deacetylase 4, follistatin, and claspin mRNAs suggests activation of molecular cascades capable of neuroprotection. We used lentiviral delivery of cAMP response element (CRE)-luciferase reporter constructs into the striatum and live animal imaging of 2-{4-[-pyridin-4-yl-1-(2,2,2-trifluoro-ethyl)-1H-pyrazol-3-yl]-phenoxymethyl}-quinoline succinic acid (TP-10)-induced luciferase activity to further demonstrate PDE10 inhibition results in CRE-mediated transcription. Consistent with potential neuroprotective cascades, we also demonstrate phosphorylation of mitogen- and stress-activated kinase 1 and H3 in vivo after TP-10 treatment. The observed changes in signaling and gene expression are predicted to provide neuroprotective effects in models of Huntington's disease. n=4-6 per group. WT mice used as a control for PDE10A KO mice, vehicle control for PDE10A inhibitor treatment.
2012-08-25 | E-GEOD-40377 | biostudies-arrayexpress
Project description:Global gene expression profiles in brains of WT mice treated with vehicle, CGG KI mice treated with vehicle, and CGG KI mice treated with 5-ALA
| PRJDB10117 | ENA
Project description:Microarray analysis of ischemic lesions of WT and TNFRI KO mice
| PRJNA102265 | ENA
Project description:Microarray of RNA from calvaria in WT and OASIS-/- (KO) mice
| PRJNA119329 | ENA
Project description:To understand the mechanisms through which JunB regulates Tregs-mediated immune regulation, we examined the global gene expression profiles in the JunB WT and KO Tregs by performing RNA sequencing (RNA-seq) analysis.
2019-05-07 | GSE129060 | GEO
Project description:To investigate the role of Irg1-itaconate or Hemin in macrophages, bone marrow-derived macrophages (BMDMs) from WT mice and Irg1 KO mice were extracted and cultured. After 7 days of cells culture, the BMDMs from WT mice were treated 120 μM 4-octyl itaconate (4-OI) for 15 h, 15 μM Hemin for 12 h, and the BMDMs from Irg1 KO mice and WT mice were treated Vehicle for 12 h. We then performed gene expression profiling analysis using data obtained from RNA-seq of 4-OI, Hemin or vehicle treated WT BMDMs and Irg1 KO BMDMs.
2024-06-28 | GSE221734 | GEO
Project description:WT-Mock-1: WT cells treated with vehicle for 24 hours, replicate-1: 126
WT-Mock-2: WT cells treated with vehicle for 24 hours, replicate-2: 127N
WT-Mock-3: WT cells treated with vehicle for 24 hours, replicate-3: 127C
WT-Mock-4: WT cells treated with vehicle for 24 hours, replicate-4: 128N
WT-6-TG-1: WT cells treated with 0.5ug/mL 6-TG for 24 hours , replicate-1: 128C
WT-6-TG-2: WT cells treated with 0.5ug/mL 6-TG for 24 hours , replicate-2: 129N
WT-6-TG-3: WT cells treated with 0.5ug/mL 6-TG for 24 hours , replicate-3: 129C
WT-6-TG-4: WT cells treated with 0.5ug/mL 6-TG for 24 hours , replicate-4: 130N
NUDT5-Mock-1: NUDT5 KO cells treated with vehicle for 24 hours, replicate-1: 130C
NUDT5-Mock-2: NUDT5 KO cells treated with vehicle for 24 hours, replicate-2: 131N
NUDT5-Mock-3: NUDT5 KO cells treated with vehicle for 24 hours, replicate-3: 131C
NUDT5-Mock-4: NUDT5 KO cells treated with vehicle for 24 hours, replicate-4: 132N
NUDT5-6-TG-1: NUDT5 KO cells treated with 0.5ug/mL 6-TG for 24 hours , replicate-1: 132C
NUDT5-6-TG-2: NUDT5 KO cells treated with 0.5ug/mL 6-TG for 24 hours , replicate-2: 133N
NUDT5-6-TG-3: NUDT5 KO cells treated with 0.5ug/mL 6-TG for 24 hours , replicate-3: 133C
NUDT5-6-TG-4: NUDT5 KO cells treated with 0.5ug/mL 6-TG for 24 hours , replicate-4: 134N
2025-03-24 | MSV000097432 | MassIVE
Project description:Expression data from untreated and DSS-treated Adamts12 WT and KO mice
| PRJNA174225 | ENA
Project description:Expression data from WT and RGS5 KO mice treated with DOCA/salt
| PRJNA350226 | ENA